Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice

Bone

Volumn 47, Issue 2, 2010, Pages 341-352

  Xu, Manshan ^a   Choudhary, Shilpa ^a   Voznesensky, Olga ^a   Gao, Qi ^a   Adams, Douglas ^a   Diaz Doran, Vilmaris ^a   Wu, Qian ^a   Goltzman, David ^b   Raisz, Lawrence G ^a   Pilbeam, Carol C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Bone remodeling; Cyclooxygenase; Prostaglandin

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PARATHYROID HORMONE; BIOLOGICAL MARKER; CYCLOOXYGENASE 1; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CATABOLISM; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMUR; HORMONE ACTION; HORMONE SYNTHESIS; HYPERPARATHYROIDISM; KNOCKOUT MOUSE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; TRABECULAR BONE; WILD TYPE; ANIMAL; BLOOD; BODY WEIGHT; BONE REMODELING; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEALTH; HUMAN; HYPERTHYROIDISM; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; BONE REMODELING; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMUR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEALTH; HUMANS; HYPERTHYROIDISM; KIDNEY; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; ORGAN SIZE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHENOTYPE; RANK LIGAND; RNA, MESSENGER;

EID: 77955984184     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.006     Document Type: Article

References (73)

1. Pilbeam C.C., Choudhary S., Blackwell K.A., Raisz L.G. Prostaglandins and bone metabolism. Principles of bone biology 2008, 1235-1271. Elsevier/Academic Press, San Diego, CA. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
2. Herschman H.R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 1994, 13:241-256.
3. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
4. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002, 68-69:95-114.
5. Okada Y., Lorenzo J.A., Freeman A.M., et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 2000, 105:823-832.
6. Choudhary S., Wadhwa S., Raisz L.G., Alander C., Pilbeam C.C. Extracellular calcium is a potent inducer of cyclooxygenase-2 in murine osteoblasts through an ERK signaling pathway. J. Bone Miner. Res. 2003, 18:1813-1824.
7. Xu Z., Choudhary S., Okada Y., et al. Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro. Bone 2007, 41:68-76.
8. Klein D.C., Raisz L.G. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 1970, 86:1436-1440.
9. Raisz L.G., Martin T.J. Prostaglandins in bone and mineral metabolism. Bone and mineral research, annual 2 1983, 286-310. Elsevier Science Publishers, Amsterdam, The Netherlands. W.A. Peck (Ed.).
10. 2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 1998, 246:337-341.
11. 2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 2004, 172:2504-2510.
12. 2. Endocrinology 1992, 130:443-448.
13. 2 on bone: induction of a transition from nonadherent to adherent osteoblast precursors. J. Bone Miner. Res. 1995, 10:474-487.
14. 2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts. J. Cell. Biochem. 1999, 73:36-48.
15. 2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997, 20:521-526.
16. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 2002, 109:1405-1415.
17. Choudhary S., Halbout P., Alander C., Raisz L., Pilbeam C. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J. Bone Miner. Res. 2007, 22:1002-1010.
18. Choudhary S., Huang H., Raisz L., Pilbeam C. Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro. Biochem. Biophys. Res. Commun. 2008, 372:536-541.
19. Chikazu D., Li X., Kawaguchi H., et al. Bone morphogenetic protein 2 induces cyclooxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. 2002. J. Bone Miner. Res. 2005, 20:1888-1898.
20. 2 and risedronate administration on cancellous bone in older female rats. Bone 1994, 15:489-496.
21. Jee W.S., Ma Y.F. The in vivo anabolic actions of prostaglandins in bone. Bone 1997, 21:297-304.
22. 2 on bone mass in rat long bones and calvariae. J. Endocrinol. 1998, 156:51-57.
23. 1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. Pediatr. Pathol. Lab. Med. 1996, 16:489-507.
24. 1 in infants with cyanotic congenital heart disease. J. Pediatr. 1980, 97:834-836.
25. 2 on vertebral trabecular remodeling in beagles used in a healing study. Calcif. Tissue Int. 1988, 42:363-368.
26. Yoshida K., Oida H., Kobayashi T., et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc. Natl Acad. Sci. USA 2002, 99:4580-4585.
27. Simon A.M., Manigrasso M.B., O'Connor J.P. Cyclooxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 2002, 17:963-976.
28. Einhorn T.A. Cox-2: where are we in 2003?-The role of cyclooxygenase-2 in bone repair. Arthritis Res. Ther. 2003, 5:5-7.
29. Brown K.M., Saunders M.M., Kirsch T., Donahue H.J., Reid J.S. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J. Bone Joint Surg. Am. 2004, 86-A:116-123.
30. Gerstenfeld L.C., Al-Ghawas M., Alkhiary Y.M., et al. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J. Bone Joint Surg. Am. 2007, 89:114-125.
31. Simon A.M., O'Connor J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J. Bone Joint Surg. Am. 2007, 89:500-511.
32. Pead M.J., Lanyon L.E. Indomethacin modulation of load-related stimulation of new bone formation in vivo. Calcif. Tissue Int. 1989, 45:34-40.
33. Lanyon L.E. Control of bone architecture by functional load bearing. J. Bone Miner. Res. 1992, 7:S369-S375.
34. Chow J.W., Chambers T.J. Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Amer. J. Physiol. 1994, 267:E287-E292.
35. Li L., Pettit A.R., Gregory L.S., Forwood M.R. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 2006, 17:203-216.
36. Alam I., Warden S.J., Robling A.G., Turner C.H. Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) gene. J. Bone Miner. Res. 2005, 20:438-446.
37. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473-482.
38. Norwood V.F., Morham S.G., Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 2000, 58:2291-2300.
39. Xu M., Choudhary S., Goltzman D., et al. Do cyclooxygenase knockout mice have primary hyperparathyroidism?. Endocrinology 2005, 146:1843-1853.
40. Lim H., Paria B.C., Das S.K., et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997, 91:197-208.
41. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 1987, 2:595-610.
42. Foldes J., Shih M.S., Parfitt A.M. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J. Bone Miner. Res. 1990, 5:1063-1067.
43. Wang H., Ma W.G., Tejada L., et al. Rescue of female infertility from the loss of cyclooxygenase-2 by compensatory up-regulation of cyclooxygenase-1 is a function of genetic makeup. J. Biol. Chem. 2004, 279:10649-10658.
44. Zhou H., Iida-Klein A., Lu S.S., et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 2003, 32:513-520.
45. McCauley L.K., Koh A.J., Beecher C.A., Rosol T.J. Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology 1997, 138:5427-5433.
46. Phelps E., Bezouglaia O., Tetradis S., Nervina J.M. Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3', 5'-cyclic adenosine monophosphate signaling in osteoblasts. Calcif. Tissue Int. 2005, 77:96-103.
47. Yang D., Guo J., Divieti P., Shioda T., Bringhurst F.R. CBP/P300-interacting protein CITED1 modulates PTH regulation of osteoblastic differentiation. Endocrinology 2008, 49:1728-1735.
48. Bellido T., Ali A.A., Gubrij I., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
49. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
50. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J. Musculoskelet. Neuronal Interact. 2006, 6:358-359.
51. Bikle D.D., Sakata T., Leary C., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res. 2002, 17:1570-1578.
52. Martin T.J., Quinn J.M., Gillespie M.T., Ng K.W., Karsdal M.A., Sims N.A. Mechanisms involved in skeletal anabolic therapies. Ann. N. Y. Acad. Sci. 2006, 1068:458-470.
53. Loftin C.D., Trivedi D.B., Tiano H.F., et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl Acad. Sci. USA 2001, 98:1059-1064.
54. Kennedy B.P., Payette P., Mudgett J., et al. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 1995, 270:22378-22385.
55. Myers L.K., Bhattacharya S.D., Herring P.A., et al. The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice. Bone 2006, 39:1048-1052.
56. Bell C.D., Vidal S., Kovacs K., Anderson J., Rotondo F. Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland. Endocr. Pathol. 2004, 15:29-38.
57. Gardner D.G., Brown E.M., Attie M.F., Aurbach G.D. Effects of prostaglandins on adenosine 3', 5'-monophosphate content and adenylate cyclase activity in dispersed bovine parathyroid cells. Endocrinology 1981, 109:1545-1551.
58. Brown E.M., Swartz S.L. Production of prostaglandins by dispersed cells and fragments from bovine parathyroid glands. Prostaglandins 1985, 29:35-46.
59. Maruani G., Hertig A., Paillard M., Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J. Clin. Endocrinol. Metab. 2003, 88:4641-4648.
60. Lowe H., McMahon D.J., Rubin M.R., Bilezikian J.P., Silverberg S.J. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 2007, 92:3001-3005.
61. Gomaa A.A., Hassan H.A., Ghaneimah S.A. Effect of aspirin and indomethacin on the serum and urinary calcium, magnesium and phosphate. Pharmacol. Res. 1990, 22:59-70.
62. Nusing R.M., Reinalter S.C., Peters M., Komhoff M., Seyberth H.W. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin. Pharmacol. Ther. 2001, 70:384-390.
63. bin Long I., Singh H.J., Rao G.J. Comparative effects of indomethacin and nabumetone on urine and electrolyte output in conscious rats. J. Pharmacol. Sci. 2005, 99:272-276.
64. 2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 2002, 30:567-573.
65. 2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
66. Robertson G., Xie C., Chen D., et al. Alteration of femoral bone morphology and density in COX-2-/- mice. Bone 2006, 39:767-772.
67. Chen Q., Rho J.Y., Fan Z., Laulederkind S.J., Raghow R. Congenital lack of COX-2 affects mechanical and geometric properties of bone in mice. Calcif. Tissue Int. 2003, 73:387-392.
68. Imanishi Y., Hosokawa Y., Yoshimoto K., et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J. Clin. Invest. 2001, 107:1093-1102.
69. Tetradis S., Pilbeam C.C., Liu Y., Kream B.E. Parathyroid hormone induces prostaglandin G/H synthase-2 expression by a cyclic adenosine 3', 5'-monophosphate-mediated pathway in the murine osteoblastic cell line MC3T3-E1. Endocrinology 1996, 137:5435-5440.
70. Tetradis S., Pilbeam C.C., Liu Y., Herschman H.R., Kream B.E. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3',5'-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 1997, 138:3594-3600.
71. Lee S.K., Lorenzo J.A. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures. Bone 2002, 31:252-259.
72. Yang D., Singh R., Divieti P., Guo J., Bouxsein M.L., Bringhurst F.R. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 2007, 40:1453-1461.
73. Chikazu D., Li X., Kawaguchi H., et al. Bone morphogenetic protein 2 induces cyclooxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J. Bone Miner. Res. 2002, 17:1430-1440.